Eikance 0.01%, the first pharmacotherapy registered on the Australian Register of Therapeutic Goods to slow the progression of myopia in children aged 4–14 years,1# may be initiated in children when myopia progresses ≥-1.0 D per year.1
Eikance 0.01% single-use ampoules are sealed in foil pouches and are available in packs of 30 x 0.3 mL ampoules. The ophthalmic solution is sterile and preservative-free. Eikance 0.01% is a prescription only medicine available at community pharmacies across Australia.
Contact: Aspen Account Manager
PBS information: This product is not listed on the PBS
Before prescribing please review full product information available by following the QR code above or visiting: ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenForm&t=pi&q=eikance.
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at: tga.gov.au/reporting-problems.
Reference
- Eikance Approved Product Information.
# Australian Register of Therapeutic Goods. Accessed: 11 March 2024.
Aspen Australia, St Leonards NSW 2065. AU-ATR-032024-08305
